NeoGenomics Announces Leadership Transition Appointing Vishal Sikri as President and Chief Commercial Officer of Inivata Liquid Biopsy Subsidiary - read this article along with other careers information, tips and advice on BioSpace
The 2021 Sales Awards have opened their doors for entry, continuing its legacy of uncovering and rewarding exceptional talent within the pharma sales sector. - News - PharmaTimes
Exclusive content, features, opinions and comment - hand-picked by our editors, just for you.
Pick 5 of your favourite companies. Get a daily email with all the news updates on them.
Track the industry of your choice with a daily newsletter specific to that industry.
Stay on top of your investments. Track stock prices in your portfolio.
NOTE :
This product is a monthly auto renewal product.
Cancellation Policy: You can cancel any time in the future without assigning any reasons, but 48 hours prior to your card being charged for renewal. We do not offer any refunds.
To cancel, communicate from your registered email id and send the mail with the request to assist@bsmail.in. Include your contact number for easy reference. Requests mailed to any other ID will not be acknowledged or actioned upon.
Despite a 24 per cent hit on its US business, Ahmedabad-based Torrent Pharmaceuticals Ltd (TPL) registered an over 18 per cent growth in its consolidated net profit for the third quarter ended December 31, 2020. The company s consolidated net profit for the quarter was Rs 297 crore as against Rs 251 crore in the corresponding period last year. Not only did Torrent Pharma s US revenues fall by 24 per cent to Rs 292 crore, its India revenues grew in single digits of seven per cent to stand at Rs 930 crore in the quarter. As a result, the company s consolidated total revenue from operations fell marginally by less than one per cent to close at Rs 2,003 crore in Q3 of FY 2020-21, as compared to Rs 2,019 crore in Q3 of FY 2019-20.